NASDAQ •
Healthcare •
Biotechnology •
Quote as of 06/26/2026 10:40
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization34.04 mln
Float3.65 mln
Earnings Date07/30/2026
Piotroski F-Score
3
/ 9
Below average
Beneish M-Score
-2.42
Borderline
1-Year Forecast
56.29
Transformational upside
Relative Strength
82
/ 100
Strongly outperforming
Debt / Equity
0.14
Very low leverage
ROE
-120
Deeply negative
Business Description
Aligos Therapeutics is a clinical-stage company working to develop new medicines for patients with serious liver and viral diseases that currently have limited treatment options. Founded in 2018 and based in South San Francisco, the company has several drug candidates advancing through clinical trials, targeting conditions such as fatty liver disease, obesity, hepatitis B, and coronavirus infections. Aligos works alongside research partners including Emory University and KU Leuven to support its drug discovery and development efforts.
